Phaseline

Companies › Jiangsu Healthy Life Innovation Medical Technology

Jiangsu Healthy Life Innovation Medical Technology: clinical trials, targets and expected readouts

2 active drug programs in 14 registered trials: 8 Phase 2, 3 Phase 3, 3 Phase 1; Oncology, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Gemcitabine hydrochloride
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 3Locally Advanced Pancreatic Cancer; Clear Cell Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Ovarian Brenner Tumor …Dec 2026
Tumor treating fields
Electric field-based tumor treatment using alternating electric fields
–Phase 3Locally Advanced Pancreatic CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02336087Gemcitabine hydrochloridePhase 1Pancreatic AdenocarcinomaOncologyDec 2026
NCT05653453Tumor treating fieldsPhase 3Locally Advanced Pancreatic CancerOncologyDec 2026
NCT05653453Gemcitabine hydrochloridePhase 3Locally Advanced Pancreatic CancerOncologyDec 2026
NCT04233866Gemcitabine hydrochloridePhase 2Metastatic Pancreatic AdenocarcinomaOncologyDec 2026
NCT01970722Gemcitabine hydrochloridePhase 1FIGO Stage IVA Ovarian CancerOncologyJan 2027
NCT02101775Gemcitabine hydrochloridePhase 2Ovarian Brenner TumorOncologyMar 2027
NCT01660971Gemcitabine hydrochloridePhase 1Metastatic Pancreatic AdenocarcinomaOncologyMar 2027
NCT02595892Gemcitabine hydrochloridePhase 2Ovarian Serous TumorOncologyAug 2027
NCT06591650Gemcitabine hydrochloridePhase 2Gallbladder Cancer UnresectableOncologyOct 2027
NCT07529483Gemcitabine hydrochloridePhase 2Pancreatic Cystic NeoplasmOncologyDec 2027
NCT00565851Gemcitabine hydrochloridePhase 3Clear Cell AdenocarcinomaOncologyJan 2028
NCT04559139Gemcitabine hydrochloridePhase 2Stage II Gallbladder Cancer AJCC v8OncologyJul 2028
NCT03609216Gemcitabine hydrochloridePhase 2Infiltrating Bladder Urothelial CarcinomaOncologyOct 2028
NCT02135042Gemcitabine hydrochloridePhase 2EBV InfectionInfectious diseaseJan 2029

Targets

RRM1 (1) RRM2B (1) RRM2 (1) POLA1 (1) POLD4 (1)

Companies with the same targets

Beijing Immunochina Medical Science & Technology Theravia InnoPharmax Jiangsu Hansoh Pharmaceutical Gilead Sciences

Companies built like this

3D Medicines (Sichuan) PharmaEssentia Protagonist Therapeutics Greenwich LifeSciences Orca Biosystems

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.